CN113166141A - 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 - Google Patents

一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 Download PDF

Info

Publication number
CN113166141A
CN113166141A CN201980074704.4A CN201980074704A CN113166141A CN 113166141 A CN113166141 A CN 113166141A CN 201980074704 A CN201980074704 A CN 201980074704A CN 113166141 A CN113166141 A CN 113166141A
Authority
CN
China
Prior art keywords
group
substituted
unsubstituted
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980074704.4A
Other languages
English (en)
Other versions
CN113166141B (zh
Inventor
江磊
冯志勇
金贤
乔智
寿建勇
尚珂
吴淡宜
许灵灵
徐圆
张淑芸
张毅
张宇星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Ennovabio Pharmaceuticals Co Ltd
Original Assignee
Shanghai Ennovabio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ennovabio Pharmaceuticals Co Ltd filed Critical Shanghai Ennovabio Pharmaceuticals Co Ltd
Publication of CN113166141A publication Critical patent/CN113166141A/zh
Application granted granted Critical
Publication of CN113166141B publication Critical patent/CN113166141B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明提供了一类六元并六元杂环化合物的制备和应用，具体地，本发明提供了一类如下式I所示的化合物，其中，各基团的定义如说明书中所述。所述的化合物具有TRK激酶抑制活性，可以作为治疗TRK功能异常相关疾病的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201980074704.4A 2018-11-13 2019-11-13 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 Active CN113166141B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811348040.XA CN111171020A (zh) 2018-11-13 2018-11-13 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN201811348040X 2018-11-13
PCT/CN2019/118217 WO2020098723A1 (zh) 2018-11-13 2019-11-13 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Publications (2)

Publication Number Publication Date
CN113166141A true CN113166141A (zh) 2021-07-23
CN113166141B CN113166141B (zh) 2022-07-22

Family

ID=70648672

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811348040.XA Pending CN111171020A (zh) 2018-11-13 2018-11-13 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN201980074704.4A Active CN113166141B (zh) 2018-11-13 2019-11-13 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811348040.XA Pending CN111171020A (zh) 2018-11-13 2018-11-13 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Country Status (6)

Country Link
US (1) US20220017512A1 (zh)
EP (1) EP3882247A4 (zh)
CN (2) CN111171020A (zh)
AU (1) AU2019379213B2 (zh)
CA (1) CA3120430C (zh)
WO (1) WO2020098723A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3099493C (en) * 2018-04-18 2023-08-22 Hitgen Inc. Macrocyclic kinase inhibitor
EP4368618A1 (en) * 2021-07-05 2024-05-15 Betta Pharmaceuticals Co., Ltd Six-membered aryl or heteroaryl amides, and composition and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066630A2 (en) * 2002-02-07 2003-08-14 Amgen Inc. Quinolinone derivatives for treating cell proliferation related disorders
WO2006069805A2 (en) * 2004-12-30 2006-07-06 4 Aza Ip Nv Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2012125668A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN104968345A (zh) * 2012-01-19 2015-10-07 肿瘤疗法科学股份有限公司 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂
CN110857304A (zh) * 2018-08-24 2020-03-03 北京富龙康泰生物技术有限公司 Trk抑制剂、其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU474984A3 (ru) * 1971-04-10 1975-06-25 Д-Р Карл Томэ Гмбх (Фирма) Способ получени пиридо (3,2- ) пиримидинов
RS57221B2 (sr) 2008-10-22 2020-08-31 Array Biopharma Inc Jedinjenja supstituisanog pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
KR101141409B1 (ko) 2009-10-12 2012-05-15 엘지전자 주식회사 제빙기의 세정 장치 및 그 방법
JP5894980B2 (ja) * 2010-05-24 2016-03-30 インテリカイン， エルエルシー 複素環式化合物およびその使用
GB201209609D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
BR112018016208A2 (pt) * 2016-02-08 2018-12-18 Redx Pharma Plc compostos heterocíclicos, em particular derivados 2-oxo-4,4,5,5,6,6,7,7-octahidrobenzoxazol, e seus usos como compostos antibacterianos
CA3099493C (en) * 2018-04-18 2023-08-22 Hitgen Inc. Macrocyclic kinase inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066630A2 (en) * 2002-02-07 2003-08-14 Amgen Inc. Quinolinone derivatives for treating cell proliferation related disorders
WO2006069805A2 (en) * 2004-12-30 2006-07-06 4 Aza Ip Nv Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2012125668A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN104968345A (zh) * 2012-01-19 2015-10-07 肿瘤疗法科学股份有限公司 1,5-萘啶衍生物和含1,5-萘啶衍生物的melk抑制剂
CN110857304A (zh) * 2018-08-24 2020-03-03 北京富龙康泰生物技术有限公司 Trk抑制剂、其制备方法和用途

Also Published As

Publication number Publication date
CN111171020A (zh) 2020-05-19
EP3882247A1 (en) 2021-09-22
AU2019379213A1 (en) 2021-07-01
CA3120430A1 (en) 2020-05-22
EP3882247A4 (en) 2022-08-03
CN113166141B (zh) 2022-07-22
CA3120430C (en) 2024-04-09
US20220017512A1 (en) 2022-01-20
AU2019379213B2 (en) 2023-02-02
WO2020098723A1 (zh) 2020-05-22

Similar Documents

Publication Publication Date Title
CN113166103B (zh) Egfr抑制剂及其应用
JP7487421B2 (ja) Ｐｒｍｔ５阻害剤
CN107011348B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物
CN113396147A (zh) 芳香杂环类衍生物调节剂、其制备方法和应用
WO2020239077A1 (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN112243439A (zh) 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途
JP6242885B2 (ja) ５−アザインダゾール化合物及び使用方法
EP2970260B1 (en) Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors
CN110062758A (zh) 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
CN113242857A (zh) 一类咪唑并芳环类化合物的制备和应用
CN114341127A (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
TW202023648A (zh) 心臟肌小節抑制劑
CN113166142B (zh) 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
CN117062818A (zh) 新型sos1抑制剂及其制备方法和应用
EP2785715A1 (en) Substituted pyridine derivatives as fabi inhibitors
CN117062816A (zh) 三环-酰胺-双环prmt5抑制剂
KR20220140710A (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
CN113166141B (zh) 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
WO2019062657A1 (zh) 氮杂环类衍生物、其制备方法及其医药用途
CN111825674A (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
CN112839941B (zh) 作为TGF-βR1抑制剂的化合物及其应用
CN113072551A (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
CN114716370A (zh) 含吡啶多环类衍生物抑制剂、其制备方法和应用
CN111269233A (zh) 一类咪唑并芳环类化合物的制备和应用
US20240067632A1 (en) WEE1 Degrading Compounds and Uses Thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant